Gilead’s Investigational Antiviral Remdesivir Receives FDA Emergency Use Authorization For COVID-19 Treatment

Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for the investigational antiviral remdesivir to treat COVID-19. The EUA will facilitate broader use of remdesivir to treat hospitalized individuals with severe COVID-19 disease, enabling access to remdesivir at additional hospitals across the country.

Allocation of the currently limited available supply of remdesivir will be made based on guiding principles that aim to maximize access for appropriate individuals in urgent need of treatment, with direction from and in collaboration with the government. Remdesivir is authorized for the treatment of . . .